Global Human Growth Hormone (HGH) Market Outlook 2022

Abstract
Human Growth Hormone (HGH) or Somatotropin is a naturally occurring polypeptide hormone that is synthesized and secreted by the anterior pituitary gland. It is largest protein in the human body made up of a chain of 191 amino acids. HGH is a unique and vital hormone protein, stimulating the growth, development and regeneration of healthy cells throughout the human body. Secretion of HGH into the bloodstream increases throughout childhood, peaks during adolescence, and steadily declines with ageing. Regulation of GH secretion is done by hypothalamus and the mediators of GH actions with major factors including GH releasing hormone (GHRH), somatostatin (SRIF), GH releasing peptide (ghrerin) and insulin-like growth factor (IGF-I). Several other factors such as stress, puberty, obesity, and a variety of signalling molecules also modulate GH release.

Owing to growth stimulating properties of HGH, excessive secretion leads to acromegalic gigantism; while deficiency of GH leads to Growth Hormone Deficiency (GHD), which is a chronic disease affecting both children and adults. GHD in children is characterized by reduced growth performance and a loss of height in comparison to peers. GHD during adulthood manifests symptoms like weight gain, reduced energy levels, disturbed sleep, etc. Standard therapies for treatment of GHD includes administration of recombinant human growth hormone through injections, releasers, sprays, etc.

Growth of the global Human Growth Hormone market is driven by increase in prevalence of pituitary dysfunction, growing geriatric population, high market opportunity due to lower rHGH market penetration across nations, rising healthcare expenditure and affordability. Major factors restraining growth of the market are high treatment cost of rHGH, adverse side-effects of synthetic HGH, illicit use of HGH, poor adherence to therapy by patients and stringent regulatory approvals involved.

In the report, human growth hormone market assessment is done across major markets such as Europe, The US and Japan. The US is the world’s largest HGH market accounting for more than one-third of global HGH market value. In-depth analysis of HGH therapy in aforementioned regions is done on the basis of overall HGH market value as well as pediatric HGH market.

Global human growth hormone therapy industry is highly consolidated with three major players – Novo Nordisk, Pfizer and Eli Lilly and Company dominating the market. These industry players as well as other leading players such as Merck KGaA and Roche are profiled herein based on attributes such as business overview, product segments, financial and business strategies. The report also compiles performance comparison of aforementioned companies and other leading companies in the segment based on various parameters in the competitive landscape section. In totality, the report provides detailed market analysis, with relevant forecasted data supported by key market dynamics. This information will be helpful in evaluating opportunities in global HGH therapy market.

Content
1. Executive Summary
2. Research Methodology
3. Human Growth Hormone
3.1 Overview
3.2 The Pathophysiology of Growth Hormone
3.2.1 Molecular Basis of GH Action
3.2.2 Metabolic Effects of GH
3.3 Growth Hormone Deficiency
3.3.1 Pediatric GHD
3.3.2 Adult GHD
3.3.3 Other Diorders
3.4 Recombinant HGH
3.4.1 Inclusion Body Technology
3.4.2 Protein Secretion Technology
3.4.3 Mouse-Cell Technology
4. Human Growth Hormone Market Analysis
4.1 Market Sizing
4.1.1 Market Size by Value (Actual & Forecasted)
4.1.2 Market Size by Volume (Actual & Forecasted)
4.1.3 Market Share by Region
4.2 HGH Market by Segment
4.2.1 Market Share
4.2.2 Pediatric GHD market
4.2.3 Adult GHD market
5. GH Deficiency Therapy
5.1 Diagnosis
5.2 Therapy for Various GHDs
5.3 Treatment Options
5.3.1 HGH Injections
5.3.2 HGH Releasers
5.3.3 Homeopathic HGH
5.3.4 Others
5.4 Human Growth Hormone (HGH) Replacement
5.4.1 Overview
5.4.2 Benefits of HGH Replacement
6. Global HGH Market Regional/Country Analysis
6.1 Europe
6.1.1 Overview
6.1.2 rhGH Market Sizing (Actual & Forecasted)
6.1.1 Pediatric rhGH Market Sizing (Actual & Forecasted)
6.2 The US
6.2.1 Overview
6.2.2 rhGH Market Sizing (Actual & Forecasted)
6.2.1 Pediatric rhGH Market Sizing (Actual & Forecasted)
6.3 Japan
6.3.1 Overview
6.3.2 rhGH Market Sizing (Actual & Forecasted)
6.3.1 Pediatric rhGH Market Sizing (Actual & Forecasted)
7. Global HGH Market Dynamics
7.1 Industry Trends & Developments
7.1.1 Advent of Long-acting rhGH
7.1.2 Use of HGH as Performance Enhancers
7.1.3 Products Under Development
7.2 Growth Drivers
7.2.1 Prevalence of Pituitary Dysfunction
7.2.2 Low Market Penetration
7.2.3 Growing Geriatric Population
7.2.4 Rising Healthcare Expenditure and Affordability
7.3 Challenges
7.3.1 High Treatment Cost
7.3.2 Adverse Side-effects of rhGH
7.3.3 Illicit Uses of HGH
7.3.4 Reimbursement Issues for Patients
7.3.5 Poor Adherence to Therapy by Patient
7.3.6 Stringent Regulatory Approvals
8. Competitive Landscape
8.1 Brand Analysis
8.2 Drugs by Disorders
8.3 Market Share by Competitors
9. Company Profiles
9.1 Merck Serono
9.2 Novo Nordisk
9.3 Pfizer
9.4 Eli Lilly
9.5 F. Hoffmann-La Roche Ltd.
List of Charts
Figure 1: Rockville Research – Research Methodology
Figure 2: Regulation of GH Secretion
Table 1: Regulation of the GH/IGF-I Axis
Figure 3. Multiple Sites of Growth Hormone Action
Table 2: Approved Doses for GHD by Nations
Figure 4: Global Human Growth Hormone (rhGH) Market Size by Value, 2012-16 (US$ Billions)
Figure 5: Global Human Growth Hormone (rhGH) Market Size by Value Forecasted, 2017E-22E (US$ Billions)
Figure 6: Global Human Growth Hormone (rhGH) Market Size by Volume, 2012-16 (US$ Billions)
Figure 7: Global Human Growth Hormone (rhGH) Market Size by Volume Forecasted, 2017E-22E (US$ Billions)
Figure 8: Global HGH Market Share by Region (2015)
Figure 9: Global HGH Market Share by Segment (2015)
Table 3: Benefits of GH Therapy for Established Indications
Figure 10. Diagnostic Approach to Short Stature Diagnosis Standard Therapies
Table 4: Various Tests for Diagnosis of Growth Hormone Deficiency
Figure 11: Europe rhGH Market Size by Value, 2012-16E (US$ Billions)
Figure 12: Europe rhGH Market Size by Value Forecasted, 2017E-22E (US$ Billions)
Figure 13: Europe Pediatric rhGH Market Size by Value, 2012-16E (US$ Billions)
Figure 14: Europe Pediatric rhGH Market Size by Value Forecasted, 2017E-22E (US$ Billions)
Figure 16: The US rhGH Market Size by Value, 2012-16E (US$ Billions)
Figure 17: The US rhGH Market Size by Value Forecasted, 2017E-22E (US$ Billions)
Figure 18: The US Pediatric rhGH Market Size by Value, 2012-16E (US$ Billions)
Figure 19: The US Pediatric rhGH Market Size by Value Forecasted, 2017E-22E (US$ Billions)
Table 5: rhGH Current Dose & Regimen Approved in Japan
Figure 20: Japan rhGH Market Size by Value, 2012-16E (US$ Billions)
Figure 21: Japan rhGH Market Size by Value Forecasted, 2017E-22E (US$ Billions)
Figure 22: Japan Pediatric rhGH Market Size by V0alue, 2012-16E (US$ Billions)
Figure 23: Japan Pediatric rhGH Market Size by Value Forecasted, 2017E-22E (US$ Billions)
Figure 24: Somavartan rhGH Sequence
Table 6: Comparison of Somavartan with Daily rhGh
Table 7: Year 2 – Somavartan Efficacy Comparison with daily rhGH
Table 8: Sports Enhancement Products
Figure 25: Prevalence of Anterior Pituitary Hormone Deficiencies
Figure 26: Market Penetration of rHGH Across Nations
Figure 27: Decline of HGH Levels with Age
Figure 28: Global Ageing Population, 2010-50
Figure 29: Global Healthcare Expenditure, 2005-16E (US$ Trillion)
Figure 30: Global Gross National Income, 2005-15 (US$ Billion)
Table 9: Prices for Popular Recombinant Human Growth Hormones
Table 10: Adverse Effects of GH Therapy
Figure 31: Poor Compliance with Daily rhGH Injections (Percent Skipping Injections)
Table 11: FDA-Approved Growth Hormone Deficiency Indications by Product
Table 12: Leading HGH Brands by Company
Table 13: List of Growth Hormones Generics by Indication & Dosage
Table 14: Drugs for Paeder Will Syndrome (PWS)
Table 15: Drugs for Turner’s Syndrome
Table 16: Drugs for Idiopathic Short Stature (ISS)
Table 17: Drugs for Small for Gestational Age (SGA)
Figure 32: Global rhGH Market Value Share by Competitors (2016)
Figure 33: Global rhGH Market Volume Share by Competitors (2016)
Figure 34: Merck Serono Revenue by Business Segment (FY2016)
Figure 35: Merck Serono Revenue by Business Segment (FY2016)
Figure 36: Novo Nordisk Human Growth Hormone Sales, FY2012-FY2016 (US$ Billion)
Table 18: Novo Nordisk – Growth Disorder R&D Pipeline
Table 19: Pfizer – Growth Hormone Deficiency Pipeline (as of 31st January, 2017)
Figure 37: Roche Revenue by Busisness Segment (FY2016)
Figure 38: Roche Ltd. Sales, FY2012-FY2016 (US$ Billions)